The Q3 results reveal significant financial developments with mixed implications. Net sales of INPEFA at $1.7 million show early market penetration, while the $25 million upfront payment from Viatris plus potential $197 million in milestones creates meaningful revenue opportunities. However, increased R&D expenses to $25.8 million and SG&A costs of $39.6 million led to a wider net loss of $64.8 million. The cash position remains strong at $258.4 million, providing runway for key clinical programs. The 50% reduction in field force signals a strategic pivot to optimize commercial spend, though severance costs impacted Q3 expenses. The Viatris deal demonstrates business development capabilities while expanding global market reach.